The proposal can significantly increase the state's costs for medicines in the USA ahead of Donald Trump taking over the White House – and also make potential cuts to healthcare insurance unpopular among many voters.
Currently, the health insurance Medicare covers preparations such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro for patients with a diabetes diagnosis. With the Biden proposal, approximately 7.4 million more Americans would receive support covering 95 percent of the cost of using the same preparations to treat obesity.
The Novo Nordisk share rises 3.4 percent after the announcement and Eli Lilly increases 2.0 percent in futures trading on Wall Street.
